Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

Hyderabad [Telangana], April 27: Dr. D. Srinivas Reddy, Chairman, and CEO of Optimus Pharma announced that they have filed for seeking emergency approval for Phase 3 Clinical Trial from the Drugs Controller General of India. Once the approval is granted for Phase 3 Clinical Trial, we would be extensively accelerating the manufacturing of our in-house developed generic version of Molnupiravir for making it available in the Indian market as soon as possible. Optimus Pharma is committed to halting the pandemic across the nation and ensuring immediate relief to all those who have been infected with the highly virulent SARS-CoV-2.

Optimus Pharma is pleased to announce the development of oral Molnupiravir on the fast lane. Optimus Pharma is becoming a key player in the fight against the COVID-19 pandemic in India has already achieved very high production levels of Favipiravir one of our flagship drugs for COVID-19 infection. In a bid to develop and diversify our anti-viral portfolio especially against SARS-CoV-2, we are here with yet another promising drug to compensate for the lack of antiviral drugs in the market further diversifying our antivirals portfolio. In hindsight of the raging second wave, Molnupiravir has been developed for non-hospitalized mild to moderate infections of SARS-CoV-2. Optimus Pharma is aggressively pushing for achieving scalability for 800mg dose of the drug.

Our available pre-clinical data on Molnupiravir already demonstrated that there were no adverse clinical signs and mortality observed in any of the treatment groups, as compared to the control group of animals with high efficacy and thereby effectively neutralizing virulence of the SARS-CoV-2 virus in the test group as compared to control group.

The drug is effective against a variety of viruses that use an RNA-dependent RNA polymerase (RdRp), as is the case with SARS-CoV-2 which is directly responsible for the transcription of Viral m-RNA of the virus in the infected subject. Early in vitro tests of Molnupiravir on SARS-CoV-2 revealed a steady decrease in virus output that was proportional to the dose of Molnupiravir used. Since the RdRp of SARS-CoV-2 and SARS-CoV, which the drug was designed to treat, has 99.1% nucleotide similarity hence, this was possible. Repeated drug exposure quickly neutralized virus populations, ensuring that none of the random mutations mediate drug resistance. As the drug is introduced in higher amounts, the titer levels and genome output of SARS-CoV-2 decrease exponentially.

It has been observed that Molnupiravir is only marginally successful in preventing extreme SARS-CoV-2 infection that is severe cases of the infection. This might have been the reason for their withdrawal and continue the trial only with non-hospitalized patients that are subjects with mild to moderate infection. We aim to do the same and establish its efficacy in the same treatment group.

Phase 2 Clinical Trial study on enrolled 202 non-hospitalized adults is already made available by the innovator of the molecule. Virological analysis was characterized by a marked decrease in positive viral culture in subjects who received Molnupiravir (all doses) relative to placebo – at day 5: 0% (0/47) for Molnupiravir and 24% (6/25) for placebo. Furthermore, the secondary objective for a faster decrease in infectious virus among people with early COVID-19 who were treated with Molnupiravir is encouraging and Phase 3 Clinical Trials are warranted for checking the efficacy of the molecule across demographics, particularly as the SARS-CoV-2 virus continues to spread and evolve globally.

Unlike the current drugs being administered intravenously, Molnupiravir is administered orally. This makes it a promising drug to halt the disease progression in the early stages as well as mount a powerful response against moderate infection levels. The fact that this molecule can be consumed as an orally administered drug in the form of an 800mg capsule renders a maverick advantage to achieve scalability in terms of upscaling from gm scale to multi-ton levels in a short time frame, thereby ensuring availability in the Indian market at a comparatively exponential scale. In vitro assays indicate that it is significantly more effective than the drugs being used currently, and the safety profile appears to be satisfactory.

43 thoughts on “Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

  1. Attractive component to content. I just stumbled upon your weblog and in accession capital to say that I get actually enjoyed account your weblog posts.
    Anyway I’ll be subscribing to your augment and even I success you access consistently rapidly.

  2. Very nice post. I just stumbled upon your blog and wanted
    to say that I have really loved surfing around your weblog posts.

    In any case I’ll be subscribing in your feed and I am hoping you write once more soon!

  3. I’m very pleased to uncover this website. I want to to thank you for your time for this
    particularly wonderful read!! I definitely appreciated every bit of it and I have you book marked to see
    new information on your site.

  4. An outstanding share! I have just forwarded this onto a co-worker who was conducting a little homework on this.
    And he actually ordered me lunch due to the fact that I discovered it for him…
    lol. So allow me to reword this…. Thanks for the meal!!

    But yeah, thanks for spending the time to talk about this matter here on your website.

  5. Heya i’m for the first time here. I came across this board
    and I find It really useful & it helped me out a lot.
    I hope to give something back and help others like you aided me.

  6. I’m not sure exactly why but this blog is loading very
    slow for me. Is anyone else having this issue or is it a issue on my end?
    I’ll check back later and see if the problem still exists.

  7. Hey! I just wanted to ask if you ever have any trouble with
    hackers? My last blog (wordpress) was hacked and I ended up losing several weeks of hard work due to no data backup.
    Do you have any solutions to prevent hackers?

  8. Hello there! This is my first comment here so I just wanted to give a
    quick shout out and tell you I truly enjoy reading your posts.
    Can you recommend any other blogs/websites/forums that cover
    the same topics? Thanks a lot!

  9. I don’t even know how I ended up here, but I thought
    this post was great. I do not know who you are but definitely you are going to a famous blogger if
    you aren’t already 😉 Cheers!

    Feel free to surf to my web site: coupon

Leave a Reply

Your email address will not be published.